Prolevi Bio

Sahil Gupta has a PhD from Goethe University Frankfurt with over 10 years of experience in life sciences, immunology, and genetic engineering. Sahil is responsible for overall company management, business, and technical development.

Daniel is Associate Professor at University of Copenhagen with more than 4 decades of experience in pharmaceutical products and inventor of more than 100 patents. Among other things, he is the inventor of the Egalet® technology, possibly the first to propose injection-moulding to produce oral controlled release dosage forms and to implement it in practice. He is also the inventor of the Parvulet® technology, a carrier of multiparticulate controlled release approaches. His activities have resulted in several marketed products and technologies. Daniel is Prolevi’s lead on the formulations, drug delivery and designs.

Dr Birte Nygard (MD, PhD) is a Consultant and Associate Professor at Herlev Hospital, University of Copenhagen. With research focused on hypothyroidism, Birte has published over 93 scientific articles, served as the President of The Danish Thyroid Association (2007 – 2013), and co-authored the European Guidelines on T3 treatment (2012), American Thyroid Association – European Thyroid Association Consensus Statement on T3 treatment (2021), and initiated the Danish National Guidelines of Treatment of Hypothyroidism.

Dr Giulia Brigante (MD, PhD) is the Chair of Endocrinology and Assistant Professor in Endocrinology at University of Modena and Reggio Emilia and University Hospital of Modena, Italy. With clinical and research specializations in pathology and genetics of thyroid diseases, her research has shed light on peripheral effects of thyroid hormones and thyroid hormone replacement therapy. Authoring over 47 scientififc articles, Giulia is a member of Italian Society of Endocrinology, European Society of Endocrinology, European Thyroid Association, and the Italian Thyroid Association.

Dr Wilmar M. Wiersinga (MD, PhD, FRCP) is the author of the current guidelines on dosing regimen for T4 (levaxine), and Professor-Emeritus of Endocrinology at the University of Amsterdam. He has presided over the Dutch Endocrine Society, and the European Thyroid Association, as well as a member of several national thyroid associations. His editorial experience include leading journals in thyroid and endocrinology, and he has authored European guidelines on thyroid hormone use (2012).

Kush is a Venture Builder and Serial Entrepreneur within Medtech, Life Sciences and Cleantech. He has co-founded over 5 successful startups that led to 2 IPOs and 1 acquisition, prior to which his research focussed on microfluidic technology and biosensing.

Edvard Hall has a background as a lawyer, management consultant, entrepreneur and investor with experience in building, running and developing innovative companies. He holds a law degree and a bachelor’s degree in finance from Lund University as well as an MSc International Development from the London School of Economics and Political Science.  Edvard has previously co-founded and run companies active in narrative analysis, strategy advice and medical technology. He is the CEO of the Nasdaq First North listed company Bioextrax. 

Anna has an extensive experience from the life science sector, and a background in R&D, business development and internationalization. Currently Anna is an investment manager at Almi Invest. Anna has previously held positions at GE Healthcare, Medicon Village, Business Sweden and several start up and scale up companies within biotech and med tech. She hold a M.Sc. in Chemistry and a Ph.D. in Biochemistry (2003) from Lund University.

Co-founding investor. Business Advisor. MSc Neuroscience, MSc Finance, entrepreneur and investor. >25 years of experience from the biotech and healthcare sectors. Support regarding financing, go-to market strategies and regulatory matters.

Stefan has extensive experience in the pharmaceutical and healthcare industry, including roles as an investor, business angel, and founder. He has a strong background in marketing strategy, change management, market access, and pharmaceutical industry expertise.
Prior to his entrepreneurial ventures, he held key leadership positions at Boehringer Ingelheim, retiring as Managing Director and Head of Human Pharma in the MIDI region.

Klaus Dugi is CEO of Vandria and a Board member at AOBiome Therapeutics and Ferring Ventures. Since 2021, Klaus is also Chief Medical Advisor & Venture Partner at +ND Capital in Lausanne. He chairs the SAB of DiogenX and is a member of the SAB of OM Pharma. 

Prior to this, he spent 18 years in pharmaceutical industry with Boehringer Ingelheim and Ferring Pharmaceuticals, mostly in leadership positions including more than 8 years as Chief Medical Officer. 

Lars Moberg has Masters in business administration from Lund University and CEO of Ekonomihuset Moberg AB, Malmö since 1991. Lars is responsible for Prolevi’s financial accounting.